Dulaglutide vs Liraglutide

Head-to-head evidence comparison — which supplement is right for you?

Quick answerNo interaction data — ask a pharmacist

Dulaglutide vs Liraglutide: Liraglutide has the stronger overall evidence (7.5 vs 7/10); they're alternatives for manage blood sugar — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.

Liraglutide Edges Ahead

Liraglutide wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.

Dulaglutide0 wins

Liraglutide2 wins

Which is right for you? Take the 60-second quiz Open in the full comparison tool

Dul7.0

Dulaglutide

Too few graded studiesLimited safety

Lir7.5

Liraglutide

Too few graded studiesLimited safety

Evidence

Evidence Score

7/10

Studies: 143

Meta-analyses: 15

Level: Strong

Evidence Score

Best7.5/10

Studies: 436

Meta-analyses: 73

Level: Strong

Research findings

Verdict

Too few graded studies

Top outcomes

Blood sugar & glycemic controlToo few graded studies106
Weight managementToo few graded studies18
Cardiovascular outcomesToo few graded studies18

Verdict

Too few graded studies

Top outcomes

Blood sugar & glycemic controlToo few graded studies242
Weight managementToo few graded studies124
Cardiovascular outcomesToo few graded studies42

Shared outcomes (3)

Outcomes where both Dulaglutide and Liraglutide have evidence — compare verdict strength side-by-side.

Blood sugar & glycemic controlToo few graded studies106Too few graded studies242
Weight managementToo few graded studies18Too few graded studies124
Cardiovascular outcomesToo few graded studies18Too few graded studies42

Dosage & timing

Recommended Dosage:

Prescription-only, clinician-prescribed. Subcutaneous 0.75 mg once weekly to start, usually escalated to 1.5 mg; 3.0 mg and 4.5 mg once-weekly doses are available for additional glycemic lowering. DO NOT self-dose.

Warnings

This is a PRESCRIPTION DRUG, not a dietary supplement — use only under a clinician's care for an approved medical indication.
US FDA labeling includes a boxed warning about thyroid C-cell tumors: dulaglutide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.
Risk of acute pancreatitis — discontinue and seek care for severe persistent abdominal pain.
Risk of gallbladder disease (gallstones, cholecystitis).
Gastrointestinal adverse effects (nausea, vomiting, diarrhea) are very common, especially during dose escalation.
Weight loss is real but modest and includes some loss of lean mass — pair sustained weight loss with resistance training and adequate protein.
Avoid COMPOUNDED / grey-market GLP-1 products: risk of dosing errors, impurities, and unapproved salt forms. Use only pharmacy-dispensed product.
Not for cosmetic weight loss without a genuine medical indication.
May increase hypoglycemia risk when combined with insulin or sulfonylureas (dose adjustment needed).

Best Time:

Any time of day

Can take on empty stomach

Best Form:

Subcutaneous once-weekly pen (Trulicity)

Recommended Dosage:

Prescription-only, clinician-titrated, subcutaneous once daily. Diabetes (Victoza): escalate 0.6 → 1.2 → 1.8 mg/day. Weight management (Saxenda): escalate weekly to 3.0 mg/day. DO NOT self-dose.

Warnings

This is a PRESCRIPTION DRUG, not a dietary supplement — use only under a clinician's care for an approved medical indication.
US FDA labeling includes a boxed warning about thyroid C-cell tumors: liraglutide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.
Risk of acute pancreatitis — discontinue and seek care for severe persistent abdominal pain.
Risk of gallbladder disease (gallstones, cholecystitis), particularly with rapid weight loss.
Gastrointestinal adverse effects (nausea, vomiting, diarrhea) are very common, especially during dose escalation.
Weight loss includes loss of lean muscle mass — pair with resistance training and adequate protein.
FDA has warned about COMPOUNDED / grey-market GLP-1 products: risk of dosing errors, impurities, and unapproved salt forms. Use only pharmacy-dispensed product.
Not for cosmetic weight loss without a genuine medical indication.
May increase hypoglycemia risk when combined with insulin or sulfonylureas (dose adjustment needed).

Best Time:

Any time of day

Can take on empty stomach

Best Form:

Subcutaneous once-daily injection (Victoza for diabetes, Saxenda for weight)

Safety

Limited safetyTie

Drug Interactions:

Other GLP-1 receptor agonists (severe)
Insulin and sulfonylureas (moderate)
Oral medications (general) (moderate)

Side Effects:

NauseaVomiting / diarrheaGallbladder disease (cholelithiasis / cholecystitis)

Contraindications:

Personal or family history of medullary thyroid carcinoma (MTC) (a contraindication under the US label)
Multiple Endocrine Neoplasia syndrome type 2 (MEN2) (a contraindication under the US label)

Limited safetyTie

Drug Interactions:

Other GLP-1 receptor agonists (severe)
Insulin and sulfonylureas (moderate)
Oral medications (general) (moderate)

Side Effects:

NauseaVomiting / diarrhea / constipationGallbladder disease (cholelithiasis / cholecystitis)

Contraindications:

Personal or family history of medullary thyroid carcinoma (MTC) (a contraindication under the US label)
Multiple Endocrine Neoplasia syndrome type 2 (MEN2) (a contraindication under the US label)

Shared goals

Manage blood sugarDulaglutide

Dulaglutide82/100

Liraglutide80/100

Manage weightLiraglutide

Dulaglutide52/100

Liraglutide72/100

Support heart healthDulaglutide

Dulaglutide72/100

Liraglutide70/100

What you'll notice

🩸 Improved glycemic controlpositive

Weeks to months

❤️ Reduced cardiovascular eventspositive

Months to years

⚖️ Modest weight losspositive

Months

🤢 GI adverse effects (very common)trade-off

Especially during initiation/escalation

🩸 Improved glycemic controlpositive

Weeks to months

⚖️ Moderate weight losspositive

Months (titrated over weeks)

❤️ Reduced cardiovascular eventspositive

Months to years

🤢 GI adverse effects (very common)trade-off

Especially during dose escalation

Key studies

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

Lancet (2019) · Rct · n=9901

Multicentre, double-blind, placebo-controlled cardiovascular-outcomes RCT: 9,901 patients aged ≥50 with type 2 diabetes, randomized to subcutaneous dulaglutide 1.5 mg/week or placebo at 371 sites in 24 countries

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

Lancet Diabetes Endocrinol (2019) · Meta analysis

Meta-analysis of seven GLP-1 receptor agonist cardiovascular-outcomes trials (ELIXA, LEADER, SUSTAIN-6, EXSCEL, Harmony Outcomes, REWIND, PIONEER 6); 56,004 participants

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.

Lancet (2019) · Rct · n=9901

Pre-specified exploratory analysis of the REWIND trial (9,901 participants) examining the renal component of the composite microvascular outcome

All Dulaglutide studies

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER).

N Engl J Med (2016) · Rct · n=9340

Double-blind cardiovascular-outcomes RCT: 9,340 patients with type 2 diabetes and high cardiovascular risk, liraglutide or placebo added to standard care, median follow-up 3.8 years.

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes).

N Engl J Med (2015) · Rct · n=3731

56-week double-blind RCT in 3,731 adults WITHOUT type 2 diabetes (BMI ≥30, or ≥27 with comorbidities), liraglutide 3.0 mg/day vs placebo plus lifestyle (2:1)

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.

JAMA (2015) · Rct · n=846

56-week double-blind RCT in 846 adults with overweight or obesity and type 2 diabetes, liraglutide 3.0 mg, 1.8 mg or placebo (2:1:1), all with diet and activity advice.

All Liraglutide studies

Frequently asked questions

Is Dulaglutide better than Liraglutide?

Liraglutide has a higher evidence score (7.5/10 vs 7/10) and wins in 2 of 3 categories.

Is Dulaglutide or Liraglutide better for manage blood sugar?

For manage blood sugar, Dulaglutide has a higher relevance score (82 vs 80).

Can I take Dulaglutide and Liraglutide together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.

Related comparisons

Dulaglutide vs Semaglutide Dulaglutide vs Tirzepatide AREDS2 Formula vs Dulaglutide Liraglutide vs Semaglutide Liraglutide vs Tirzepatide AREDS2 Formula vs Liraglutide

Still deciding between Dulaglutide and Liraglutide?

The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.

Get your personalised pick Dulaglutide details Liraglutide details

Warnings

This is a PRESCRIPTION DRUG, not a dietary supplement — use only under a clinician's care for an approved medical indication.

US FDA labeling includes a boxed warning about thyroid C-cell tumors: dulaglutide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.

Risk of acute pancreatitis — discontinue and seek care for severe persistent abdominal pain.

Risk of gallbladder disease (gallstones, cholecystitis).

Gastrointestinal adverse effects (nausea, vomiting, diarrhea) are very common, especially during dose escalation.

Weight loss is real but modest and includes some loss of lean mass — pair sustained weight loss with resistance training and adequate protein.

Avoid COMPOUNDED / grey-market GLP-1 products: risk of dosing errors, impurities, and unapproved salt forms. Use only pharmacy-dispensed product.

Not for cosmetic weight loss without a genuine medical indication.

May increase hypoglycemia risk when combined with insulin or sulfonylureas (dose adjustment needed).

Warnings

This is a PRESCRIPTION DRUG, not a dietary supplement — use only under a clinician's care for an approved medical indication.

US FDA labeling includes a boxed warning about thyroid C-cell tumors: liraglutide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.

Risk of acute pancreatitis — discontinue and seek care for severe persistent abdominal pain.

Risk of gallbladder disease (gallstones, cholecystitis), particularly with rapid weight loss.

Gastrointestinal adverse effects (nausea, vomiting, diarrhea) are very common, especially during dose escalation.

Weight loss includes loss of lean muscle mass — pair with resistance training and adequate protein.

FDA has warned about COMPOUNDED / grey-market GLP-1 products: risk of dosing errors, impurities, and unapproved salt forms. Use only pharmacy-dispensed product.

Not for cosmetic weight loss without a genuine medical indication.

May increase hypoglycemia risk when combined with insulin or sulfonylureas (dose adjustment needed).

Frequently asked questions

Is Dulaglutide better than Liraglutide?

Liraglutide has a higher evidence score (7.5/10 vs 7/10) and wins in 2 of 3 categories.

Is Dulaglutide or Liraglutide better for manage blood sugar?

For manage blood sugar, Dulaglutide has a higher relevance score (82 vs 80).

Can I take Dulaglutide and Liraglutide together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.